-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TIGIT is a co-inhibitory receptor for T cell and natural killer cell activity
immunity
This is the first open-label, multi-center, dose-escalation, and expanded phase 1a/b clinical trial in humans, recruiting patients with locally advanced or metastatic solid tumors
Treatment-related side effects
Treatment-related side effectsA total of 33 patients were recruited (23 in stage 1a and 10 in stage 1b)
Treatment response of different tumors
Treatment response of different tumorsIn stage 1a, 7 patients (30.
In stage 1a, 7 patients (30.
All in all, Etigilimab has acceptable safety.
Etigilimab has acceptable safety.
Original source:
Niharika B.
A Phase 1a / b Open? Label , Dose? Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
in this message